Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Adam J. Townsend, Chief Commercial Officer of Apellis Pharmaceuticals, sold 3,323 shares of common stock on January 22, 2025, to cover tax withholding obligations related to released Restricted Stock Units.

Summary

• On January 22, 2025, Adam J. Townsend, the Chief Commercial Officer of Apellis Pharmaceuticals, sold 3,323 shares of the company's common stock.
• The shares were sold at a price of $30.4255 per share.
• This transaction was executed to cover tax withholding obligations associated with Restricted Stock Units that were released on January 21, 2025.
• Following the transaction, Townsend directly owns 84,745 shares of Apellis Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative outlook on the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the reason for the sale.

Key Dates

Keywords

Apellis Pharmaceuticals, Adam J. Townsend, Form 4, Share Sale, Restricted Stock Units, Tax Withholding, APLS, Chief Commercial Officer